AstraZeneca

Tucson, Arizona

OncologyPhase IIIListed · AZN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

What changed

Study registered, no phase assigned: Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer

1w agoTrial registeredJul 7, 2026Source filing (opens the source filing in a new tab)

Momentum

86no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R21 · $234k · non-dilutive
Dec 1, 2024
UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JONES, DAVID K. · NINDS · award ends Nov 30, 2026 · Probing mechanisms of long QT type 2-associated neuronal dysfunction using gene-edited stem cell-derived neurons
NIH RePORTER · NIH RePORTER 11239014 (opens the source filing in a new tab)
Trial
PHASE3 registered
Oct 15, 2024
Non-small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: AstraZeneca · A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
ClinicalTrials.gov · NCT06564844 (opens the source filing in a new tab)
Grant
R01 · $477k · non-dilutive
Jul 1, 2024
UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JONES, DAVID K. · NHLBI · award ends Jun 30, 2029 · A hERG1 potassium channel subdomain is trafficked to the cardiac nucleus: mechanisms and targets of the hERG1NP
NIH RePORTER · NIH RePORTER 11101330 (opens the source filing in a new tab)
Grant
T32 · $2.8M · non-dilutive
Jul 1, 2022
HARVARD MEDICAL SCHOOL · PI WALENSKY, LOREN DAVID · NIGMS · award ends Jun 30, 2027 · Medical Scientist Training Program
NIH RePORTER · NIH RePORTER 11110476 (opens the source filing in a new tab)
Grant
T32 · $61k · non-dilutive
Jul 1, 2022
HARVARD MEDICAL SCHOOL · PI WALENSKY, LOREN DAVID · NIGMS · award ends Jun 30, 2027 · Medical Scientist Training Program
NIH RePORTER · NIH RePORTER 11249490 (opens the source filing in a new tab)
Trial
Study registered
Jun 14, 2022
Non-Small Cell Lung Cancer · RECRUITING · sponsor: Memorial Sloan Kettering Cancer Center · Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
ClinicalTrials.gov · NCT05424029 (opens the source filing in a new tab)
Trial
Study registered
Dec 5, 2019
Insulin Dependent Diabetes · ACTIVE_NOT_RECRUITING · sponsor: University of Surrey · The Use of the Dexcom G6® in Commercial Pilots With Insulin-treated Diabetes
ClinicalTrials.gov · NCT04225455 (opens the source filing in a new tab)
Grant
P30 · $225k · non-dilutive
Jul 1, 2019
MAYO CLINIC ROCHESTER · PI JONES, DAVID T · NIA · award ends Apr 30, 2029 · Digital Innovation Core
NIH RePORTER · NIH RePORTER 11110456 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the trial record at 0.53name similarity 100% · same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Study registered, no phase assigned: Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
8w agoTrial registeredSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Probing mechanisms of long QT type 2-associated neuronal dysfunction using gene-edited stem cell-derived neurons
7mo agoGrant renewalSource (opens the source filing in a new tab)
Study registered, no phase assigned: The Use of the Dexcom G6® in Commercial Pilots With Insulin-treated Diabetes
7mo agoTrial registeredSource (opens the source filing in a new tab)
NIH T32 · $0.1M · Medical Scientist Training Program
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH P30 · $0.2M · Digital Innovation Core
11mo agoGrant renewalSource (opens the source filing in a new tab)
NIH T32 · $2.8M · Medical Scientist Training Program
11mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · A hERG1 potassium channel subdomain is trafficked to the cardiac nucleus: mechanisms and targets of the hERG1NP
Jul 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R21 · $234k · non-dilutive

PHASE3 registered

R01 · $477k · non-dilutive

T32 · $2.8M · non-dilutive

T32 · $61k · non-dilutive

Study registered

Study registered

P30 · $225k · non-dilutive